 |
1 Product |  |
0 Diseases | | 1 Product |
|
2 Trials |  |
72 News |  |
| «12 |
- || tilavonemab (ABBV-8E12) / AbbVie
Trial completion date: A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Feb 26, 2019
P2, N=400, Recruiting, Sponsor: AbbVie
Trial completion date: Sep 2022 --> Oct 2021
- | tilavonemab (ABBV-8E12) / AbbVie
Enrollment status: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Nov 23, 2018
P2, N=330, Enrolling by invitation, Sponsor: AbbVie
Trial completion date: Sep 2022 --> Oct 2021 Recruiting --> Enrolling by invitation
- | tilavonemab (ABBV-8E12) / AbbVie
Enrollment closed: A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Nov 13, 2018
P2, N=281, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- ||||| tilavonemab (ABBV-8E12) / AbbVie
New P2 trial: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) (clinicaltrials.gov) - Oct 19, 2018
P2, N=400, Not yet recruiting, Sponsor: AbbVie
- || tilavonemab (ABBV-8E12) / AbbVie
Trial completion date: A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Sep 18, 2018
P2, N=400, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial completion date: Apr 2021 --> Sep 2022
- | tilavonemab (ABBV-8E12) / AbbVie
Enrollment closed: Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 (clinicaltrials.gov) - Jul 24, 2018
P1, N=3, Active, not recruiting, Sponsor: AbbVie
Trial completion date: Apr 2021 --> Sep 2022 Recruiting --> Active, not recruiting
- || tilavonemab (ABBV-8E12) / AbbVie
New P1 trial: Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 (clinicaltrials.gov) - Jul 15, 2018
P1, N=5, Recruiting, Sponsor: AbbVie
- || tilavonemab (ABBV-8E12) / AbbVie
Trial completion date, Trial primary completion date: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Apr 2, 2018
P2, N=340, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial completion date: Sep 2024 --> Sep 2022 | Trial primary completion date: Sep 2024 --> Sep 2022
- ||| tilavonemab (ABBV-8E12) / AbbVie
Enrollment change, Trial completion date, Trial primary completion date: A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Mar 7, 2018
P2, N=330, Recruiting, Sponsor: AbbVie
Trial completion date: Sep 2024 --> Sep 2022 | Trial primary completion date: Sep 2024 --> Sep 2022 N=180 --> 330 | Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: May 2019 --> Jun 2020
- ||||| tilavonemab (ABBV-8E12) / AbbVie
New P2 trial: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Jan 30, 2018
P2, N=340, Recruiting, Sponsor: AbbVie
- |||| tilavonemab (ABBV-8E12) / AbbVie
Enrollment open, Enrollment change: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Jan 30, 2018
P2, N=340, Recruiting, Sponsor: AbbVie
N=180 --> 330 | Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: May 2019 --> Jun 2020 Not yet recruiting --> Recruiting | N=180 --> 340
- tilavonemab (ABBV-8E12) / AbbVie
New P1 trial: Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 (clinicaltrials.gov) - Jan 28, 2018
P1, N=10, Not yet recruiting, Sponsor: AbbVie
- ||||| tilavonemab (ABBV-8E12) / AbbVie
New P2 trial: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Jan 5, 2018
P2, N=180, Not yet recruiting, Sponsor: AbbVie
- | tilavonemab (ABBV-8E12) / AbbVie
Trial completion: Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy (clinicaltrials.gov) - Jul 26, 2017
P1, N=32, Completed, Sponsor: C2N Diagnostics
Not yet recruiting --> Recruiting | N=180 --> 340 Active, not recruiting --> Completed
- || tilavonemab (ABBV-8E12) / AbbVie
Trial primary completion date: A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Apr 20, 2017
P2, N=400, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Trial primary completion date: Apr 2020 --> Dec 2020
- |||| tilavonemab (ABBV-8E12) / AbbVie
Enrollment open: A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Jan 5, 2017
P2, N=180, Recruiting, Sponsor: AbbVie
Trial primary completion date: Apr 2020 --> Dec 2020 Not yet recruiting --> Recruiting
- ||||| tilavonemab (ABBV-8E12) / AbbVie
New P2 trial: A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Dec 6, 2016
P2, N=180, Not yet recruiting, Sponsor: AbbVie
- |||| tilavonemab (ABBV-8E12) / AbbVie
Enrollment open: A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Nov 1, 2016
P2, N=400, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| tilavonemab (ABBV-8E12) / AbbVie
New P2 trial: A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Aug 25, 2016
P2, N=400, Not yet recruiting, Sponsor: AbbVie
- tilavonemab (ABBV-8E12) / AbbVie
Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy (clinicaltrials.gov) - Jul 27, 2016
P1, N=32, Active, not recruiting, Sponsor: C2N Diagnostics
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Aug 2016
- tilavonemab (ABBV-8E12) / AbbVie
Enrollment closed: Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy (clinicaltrials.gov) - Jun 1, 2016
P1, N=32, Active, not recruiting, Sponsor: C2N Diagnostics
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- tilavonemab (ABBV-8E12) / AbbVie
Enrollment open: Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy (clinicaltrials.gov) - Aug 8, 2015
P1, N=32, Recruiting, Sponsor: C2N Diagnostics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- tilavonemab (ABBV-8E12) / AbbVie
New P1 trial: Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy (clinicaltrials.gov) - Jul 10, 2015
P1, N=32, Not yet recruiting, Sponsor: C2N Diagnostics